Publications by authors named "Romana Lowcock"
Rozanolixizumab is an anti-human neonatal Fc receptor humanized immunoglobulin (Ig) G4 monoclonal antibody that reduces IgG, including pathogenic IgG autoantibodies. Rozanolixizumab safety and tolerability have been assessed in previous clinical studies with predominantly White participants. We assessed safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of rozanolixizumab in healthy Japanese and Chinese participants compared with White participants.
View Article and Find Full Text PDFArticle Synopsis
- Generalised myasthenia gravis is a rare and difficult-to-manage disease that has a high treatment burden, highlighting the need for better therapies; zilucoplan, a self-administered treatment, was tested in this context.
- The RAISE trial was a phase 3 study conducted across 75 sites in multiple countries, comparing zilucoplan with a placebo in patients diagnosed with AChR-positive myasthenia gravis over a 12-week period.
- Results indicated that patients receiving zilucoplan experienced a significant reduction in their MG-ADL scores compared to those on placebo, suggesting it may be an effective treatment option.